Legend Biotech Corp - Company Profile
Powered by 
All the sales intelligence you need on Legend Biotech Corp in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Legend Biotech Corp fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Legend Biotech Corp.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Legend Biotech Corp (Legend Biotech) is a cell therapy company that develops therapies for cancer. Its pipeline products include CARVYKTI which treats newly diagnosed multiple myeloma; LB1908 which targets relapsed or refractory gastric and pancreatic cancers; LB2102 for 2L+ small cell lung cancer and large cell neuroendocrine carcinoma; LB2401, LB2402, LB2403, LB2503 and LB2502 which treats relapsed and refractory multiple myeloma; LB2404D, LB2505 and LB2405 which targets relapsed and refractory autoimmune diseases; LB2302, LB2303, LB2406 and LB2501 for relapsed and refractory b-cell non-hodgkin lymphoma; The company operates in the US, Ireland, Belgium and China. Legend Biotech is headquartered in Somerset, New Jersey, the US.
Headquarters
United States of America
Address
2101 Cottontail Lane, Somerset, New Jersey, 08873
Website
https://legendbiotech.com/
Telephone
1 732 3175050
No of Employees
3,100
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
LEGN (NASD)
Revenue (2024)
$1.0B
64%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-67.7%
(2024 vs 2023)
Market Cap*
$4.6B
Net Profit Margin (2024)
XYZ
-2.2%
(2024 vs 2023)
* As of and is in US$
Legend Biotech Corp premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | CARVYKTI |
| CARVYKTI: Newly Diagnosed Multiple Myeloma | |
| LB1908: Relapsed or Refractory Gastric and Pancreatic Cancers | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Legend Biotech Corp | Novartis AG | Bristol-Myers Squibb Co | Genetix Biotherapeutics Inc | Autolus Therapeutics Plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United States of America | United States of America | United Kingdom |
| City | Somerset | Basel | Princeton | Somerville | London |
| State/Province | New Jersey | Basel-Stadt | New Jersey | Massachusetts | England |
| No. of Employees | 3,100 | 75,267 | 32,500 | 248 | 754 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Fangliang Zhang, Ph.D. | Chairman | Executive Board | 2022 | 61 |
| Ying Huang, Ph.D. | Chief Executive Officer; Director | Executive Board | 2020 | 53 |
| Carlos Santos Garcia | Chief Financial Officer | Senior Management | 2025 | 54 |
| Guowei Fang, Ph.D. | Chief Scientific Officer; Head - Business Development | Senior Management | - | - |
| Elaine Qian | Head - Human Resources; Vice President | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer